Cargando…

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

BACKGROUND: Farnesyl protein transferase inhibitors (FTIs) were originally developed to inhibit oncogenic ras, however it is now clear that there are several other potential targets for this drug class. The FTI tipifarnib (ZARNESTRA™, R115777) has recently demonstrated clinical responses in adults w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raponi, Mitch, Belly, Robert T, Karp, Judith E, Lancet, Jeffrey E, Atkins, David, Wang, Yixin
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516036/ https://www.ncbi.nlm.nih.gov/pubmed/15329151 http://dx.doi.org/10.1186/1471-2407-4-56

Ejemplares similares

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Tipifarnib in the treatment of acute myeloid leukemia
por: Thomas, Xavier, et al.
Publicado: (2007)

Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma
por: Alonso-Alonso, Ruth, et al.
Publicado: (2020)

Tipifarnib prevents development of hypoxia-induced pulmonary hypertension
por: Duluc, Lucie, et al.
Publicado: (2017)

A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia
por: Kirschbaum, Mark, et al.
Publicado: (2011)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells
por: Krzykowska-Petitjean, Katarzyna, et al.
Publicado: (2011)

Targeting of CD34(+)CD38(-) cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
por: Jawad, Mays, et al.
Publicado: (2012)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation
por: Greenberg, Jacob W., et al.
Publicado: (2022)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Integrative molecular subtypes of acute myeloid leukemia
por: Mo, Qianxing, et al.
Publicado: (2023)

A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors
por: DING, NING, et al.
Publicado: (2014)

Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair
por: Mahmud, Hasan, et al.
Publicado: (2019)

PB1782: INTEGRATIVE MOLECULAR SUBTYPES OF ACUTE MYELOID LEUKEMIA
por: Mo, Qianxing, et al.
Publicado: (2023)

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
por: Kuenzi, Brent M., et al.
Publicado: (2019)

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)

Expression profile analysis of long non‐coding RNA in acute myeloid leukemia by microarray and bioinformatics
por: Feng, Yuandong, et al.
Publicado: (2018)

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
por: Smith, Alison E., et al.
Publicado: (2023)

In Silico Genetics Revealing 5 Mutations in CEBPA Gene Associated With Acute Myeloid Leukemia
por: Mustafa, Mujahed I, et al.
Publicado: (2019)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

Antitumor effects of low‐dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF‐1α‐expressing gastric cancer cells
por: Egawa, Noriyuki, et al.
Publicado: (2021)

Molecular Genetic Markers in Acute Myeloid Leukemia
por: Yohe, Sophia
Publicado: (2015)

Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia
por: Alarcón-Payer, Carolina, et al.
Publicado: (2022)

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Jain, Akriti G, et al.
Publicado: (2021)

Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin
por: Narayan, Rupa, et al.
Publicado: (2019)

Acute Myeloid Leukemia—Genetic Alterations and Their Clinical Prognosis
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2017)

Genetic Characterization and Risk Stratification of Acute Myeloid Leukemia
por: Pourrajab, Fatemeh, et al.
Publicado: (2020)

Therapeutic use of Aldara™ in chronic myeloid leukemia
por: Marleau, Annette M, et al.
Publicado: (2007)

Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia
por: Li, Bing, et al.
Publicado: (2014)

Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia
por: Petti, Allegra A., et al.
Publicado: (2022)

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
por: McNeer, Nicole A., et al.
Publicado: (2019)

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
por: Li, Sheng, et al.
Publicado: (2016)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy
por: Conneely, Shannon E., et al.
Publicado: (2021)

PB1847: ACUTE MYELOID LEUKEMIA – IS IT MORE BESIDES GENETIC ABNORMALITIES?
por: Urbano, M., et al.
Publicado: (2022)

Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs
por: Ishizawa, Jo, et al.
Publicado: (2015)

Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
por: Lu, Rui, et al.
Publicado: (2017)

Targeting PR1 in myeloid leukemia
por: Alatrash, Gheath, et al.
Publicado: (2017)

Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia
por: Lamba, Jatinder K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gijthsalu3ee2jmorsr5l5vcec